In-depth study of PEGylated Protein market dynamics and
growth trends. From improved pharmacokinetics to market
segmentation, explore the landscape of protein drug
innovation.
BOSTON, May 22, 2024
/PRNewswire/ -- According to the latest BCC Research study,
the demand for the PEGylated Proteins Market is
expected to grow from $10.2 billion
in 2023 and is projected to reach $15.9
billion by the end of 2028, at a compound annual growth rate
(CAGR) of 9.4% during the forecast period of 2023 to 2028.
This report explores the current and future outlook of the
PEGylated Proteins market and analyzes key drivers, restraints, and
opportunities. It covers competitive dynamics, pipeline activities,
and market forecasts for 2028. Company profiles provide insight
into business units, finances, products, and recent developments.
The global market is segmented into North
America, Europe,
Asia Pacific, and Rest of the
World. Historical data for 2020 and 2021 and forecasts for 2022 to
2028 are provided. It should be noted that pEGylated vaccines are
not included in the scope.
Researchers are actively investigating the potential of
site-specific PEGylation to increase the efficacy of protein drugs.
Researchers aim to optimize drug delivery and prolong therapeutic
activity by targeting specific sites on proteins. In addition,
there is a significant shift towards branched PEGylation,
reflecting the increasing interest of the pharmaceutical industry
in this approach. The focus on branched PEGylation is expected to
drive the development and eventual launch of new products in this
category. As researchers continue exploring innovative PEGylation
technologies, protein-based therapies are on the verge of advances
that could profoundly impact patient care and treatment
outcomes.
To learn more about the PEGylated Proteins Market Report,
click here for details.
Key Drivers of the PEGylated Proteins Market
Protein Drugs in Cancer and Hematology: PEGylated
proteins are very important in the treatment of cancer and blood
diseases because of their greater stability, longer circulation
time, and less risk of immune reactions. In cancer treatment,
PEGylated antibodies, such as monoclonal antibodies, can target
cancer cells and reduce side effects. For blood disorders,
PEGylated drugs such as erythropoietin (EPO) treat anemia, and
granulocyte colony-stimulating factor (G-CSF) treat
neutropenia.
Design of Biobetters: Biobetter is an upgraded version of
an existing biological medicine that has been deliberately modified
to improve its performance. Unlike biosimilar biomodifiers,
specific modifications such as PEGylation, glycosylation, or amino
acid substitution are performed. Benefits include improved
efficacy, reduced immune response, longer persistence in the body
(due to PEGylation), and fewer potential side effects. Their goal
is to overcome the limitations of current medicine and improve
patient outcomes.
Request a Sample Copy of the PEGylated
Proteins Market Report.
Report Synopsis
Report
Metrics
|
Details
|
Base year
considered
|
2022
|
Forecast Period
considered
|
2023-2028
|
Base year market
size
|
$9.3 billion
|
Market Size
Forecast
|
$15.9
billion
|
Growth Rate
|
CAGR of 9.4% for the
forecast period of 2023-2028
|
Segment
Covered
|
Protein Type,
PEGylation Type, Application, and Region
|
Regions
covered
|
North America, Europe,
Asia-Pacific, and Rest of the World (RoW)
|
Countries
covered
|
U.S., Canada, Mexico,
Germany, the U.K., France, China, Australia, and Japan
|
Key Market
Drivers
|
- Protein drugs in
cancer and hematology
- Design of
biobetters
|
Segmentation Analysis:
- Protein Types: Includes Granulocyte-Colony Stimulating
Factors (G-CSF), Monoclonal Antibodies (especially PEGylated for
cancer immunotherapy), Interferons (PEGylated for viral infections
and cancers), Recombinant Factors (such as PEGylated erythropoietin
for anemia), and other specific therapeutic proteins.
- PEGylation Types: Involves Linear PEGylation (for
enhanced stability and prolonged half-life)and Branched PEGylation
(for improved solubility and reduced immunogenicity).
- Applications: Cover autoimmune diseases (modulating
immune responses and reducing inflammation), hematology (treating
anemia and blood disorders), cancer therapy (targeted treatments),
and various other therapeutic areas.
- Regions: Encompasses the U.S. (robust biopharmaceutical
industry), Europe (significant
adoption in clinical practice and research), and Emerging Markets
(growing healthcare infrastructure and awareness), including
regions in Asia, Latin America, and the Middle East.
This PEGylated Proteins Market Report contains comprehensive
information and analysis covering the following key
questions:
- What is the projected market size and growth rate of the
market?
The PEGylated market is projected to grow
from $9.3 billion in 2022 to
$15.9 billion in 2028, at a compound
annual growth rate (CAGR) of 9.4% during
the forecast period.
- What are the key factors driving the growth of the market?
The increasing development of protein drugs in hematology and
cancer and their application in the design
of biobetters are driving the market
growth.
- What segments are covered in the market?
The market is segmented by protein
type, PEGylation type, application, and
region.
- By Type, which segment will dominate the market by the end of
2028?
The granulocyte-colony stimulating factor
segment will dominate the market by the end of 2028.
- Which region has the highest market share in the market?
North America has the highest
market share.
Some of the Key Market Players Are:
- Amgen Inc.
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- UCB Pharma
Browse More Related Reports
Nanoparticles in Biotechnology, Drug Development, and Drug
Delivery Systems: The comprehensive report on
nanoparticles in biotechnology, drug development, and diagnostics
offers a thorough analysis of global market trends from 2023 to
2028, with a focus on compound annual growth rate projections. It
includes insights into leading and emerging drug products,
manufacturers, and their specific offerings. Furthermore, the
report assesses the competitive landscape, highlighting the impact
of new product introductions on patient quality of life. Regional
analysis spans North America,
Europe, Asia-Pacific, and the Rest of the World,
providing a holistic view of market dynamics across different
geographical regions.
Global Markets for Bioengineered Protein Drugs:
This comprehensive report on the global market for Bioengineered
Protein Drugs, offers both quantitative and qualitative insights to
aid readers in crafting effective business strategies. Segmenting
the market based on drug type, disease type, and region, provides a
nuanced understanding of the landscape, enabling stakeholders to
assess their positioning and make informed decisions. Industry
growth drivers, restraints, trends, and opportunities are
meticulously analyzed, while detailed company profiles offer
insights into the competitive landscape. Additionally, the report
addresses the impact of COVID-19 on the market, ensuring a
comprehensive assessment of current market dynamics.
Directly Purchase a copy of the
report with BCC Research.
For further information or to make a purchase, please get in
touch with
info@bccresearch.com.
About BCC Research
BCC Research provides objective, unbiased measurement and
assessment of market opportunities with detailed market research
reports. Our experienced industry analysts' goal is to help you
make informed business decisions, free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St. Ste 16,
Boston, MA 02109, USA
Email: info@bccresearch.com,
Phone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit
our media page for access to our market research library.
Data and analysis extracted from this press release must be
accompanied by a statement identifying BCC Research LLC as the
source and publisher.
Logo:
https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/pegylated-proteins-market-driving-innovations-in-therapeutic-solutions-302152604.html
SOURCE BCC Research LLC